Physician profile
Mark H Mines
NPI 1578536611
$2,413.65
in general payments reported to CMS, 2019-2025
23 companies · $335 in 2025
The $335 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $420 · 2020: $201 · 2021: $111 · 2022: $409 · 2023: $550 · 2024: $389 · 2025: $335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,273.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $318.26 | 2019-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $284.45 | 2019-2025 | Jardiance |
| Boston Scientific Corporation | $282.64 | 2019-2025 | Watchman Flx, Watchman Access System, Farapulse |
| Merck Sharp & Dohme LLC | $224.67 | 2022-2025 | Verquvo |
| Novartis Pharmaceuticals Corporation | $171.62 | 2019-2025 | |
| Pfizer INC. | $169.41 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $152.54 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $115.40 | 2019-2023 | Xarelto |
| Medtronic, INC. | $106.43 | 2023-2024 | Resolute Onyx |
| Portola Pharmaceuticals, LLC | $67.94 | 2019-2020 | |
| Lantheus Medical Imaging, INC. | $65.73 | 2022-2025 | Definity |
| Alnylam Pharmaceuticals INC. | $64.99 | 2022-2024 | Onpattro |
| Amgen INC. | $51.76 | 2019-2023 | Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $51.42 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $50.42 | 2019-2024 | Farxiga |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiovascular Systems INC. | $45.05 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $40.70 | 2019 | |
| Abiomed | $37.38 | 2019-2021 | |
| Abbott Laboratories | $35.75 | 2022-2023 | Mitraclip |
| Kestra Medical Technology Services, INC. | $26.92 | 2024 | Assure Wcd |
| Regeneron Healthcare Solutions, INC. | $22.67 | 2019 | |
| Chiesi USA, INC. | $17.30 | 2023 | Kengreal |
| Sensible Medical Innovations INC | $10.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Mines listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.